Industry reaps rewards from integrating Japan in early trials
This article was originally published in SRA
Executive Summary
Pharmaceutical companies need to consider whether and how to include Japan in their international clinical trial programmes at the earliest possible stage, as this can lead to worthwhile dividends down the line as the industry pursues the simultaneous global development of new products.